Peptide-MHC Multimer Proximity Ligation Assay for Rare Cell Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antigen-specific cells, such as peptide-MHC tetramer staining, face challenges with non-specific staining and variable signal-to-noise ratios, making it difficult to identify rare cells effectively.
Innovation Solution
The use of synthetic constructs and proximity ligation assays (PLA) that involve contacting target cells with a peptide-MHC multimer and a targeting component specific for a receptor, forming a nucleic acid template by ligating oligonucleotides, and amplifying the signal to enhance specificity and detection of antigen-specific cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If peptide-MHC tetramer staining is used to detect antigen-specific cells, then direct detection of antigen-specific cells is achieved, but non-specific staining occurs and signal-to-noise ratio varies significantly
Solution Approach 1:
The detection method is segmented into multiple independent binding events: first the peptide-MHC multimer binds to the TCR, then the targeting component binds to a second antigen. Each binding event is detected separately with its own oligonucleotide probe, allowing the signal to be divided and verified through multiple specific interactions rather than relying on a single staining event.
Solution Approach 2:
Oligonucleotide probes serve as intermediaries that bridge the antibody binding events and the detection system. The first oligonucleotide probe binds to the peptide-MHC multimer-TCR complex, while the second oligonucleotide probe binds to the targeting component-second antigen complex. These probes then hybridize to form a detectable nucleic acid template, providing a specific molecular bridge that eliminates non-specific staining.
2Measurement precision
If traditional tetramer staining is used, then detection capability is provided, but the signal-to-noise ratio varies significantly hampering detection of rare cells
Solution Approach 1:
Two separate detection signals are merged into a single nucleic acid template through hybridization of the first and second oligonucleotide probes. This combining of independent specific binding events creates a unified detectable signal that represents the simultaneous occurrence of both specific interactions, thereby eliminating non-specific background and dramatically improving the signal-to-noise ratio for rare cell detection.
Solution Approach 2:
The detection parameter is changed from measuring antibody binding intensity (which varies and produces noise) to measuring the presence of a specific nucleic acid hybridization product. This parameter change from continuous fluorescence intensity to discrete hybridization detection provides a binary, highly specific readout that eliminates signal-to-noise variation and enables reliable detection of rare antigen-specific cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces false positives by eliminating non-specific binding and improves the signal-to-noise ratio, allowing for more accurate detection and isolation of rare antigen-specific cells.
Implementation Method 1
contacting the target cell with a cell selector component for which the target cell is specific, the cell selector component being bound to a first oligonucleotide; contacting the target cell with a targeting component specific for a second antigen on the target cell
Implementation Method 2
forming a nucleic acid template by ligating the first oligonucleotide and the second oligonucleotide
Implementation Method 3
amplifying the nucleic acid template
Data Source
AI summary
The present disclosure provides methods for detecting antigen-specific cells, such as T cells or B cells, using a proximity ligation assay (PLA) in which at least one of the PLA probes is a peptide-major histocompatibility (MHC) multimer or a B cell specific antigen bound to an oligonucleotide. Also provided are kits for use in such methods.